Omvoh's approval as a treatment for Crohn's disease was based on results from a study in which 53% of patients treated with the drug achieved clinical remission, and 46% of patients had visible ...
A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove ...
Some other medicines that are slated to become blockbusters in the near future include GSK’s vaccine candidate GSK-3536819 ...
In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other healthcare stocks Jim Cramer has made bold predictions about. Healthcare has been ...
Missiles have become the leading cause of death among airline passengers with more than 500 cases recorded in the last decade, the most recent of which was the Azerbaijan Airlines allegedly shot ...
The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved and that specialty pharmacies and online companies need to stop ...
Eli Lilly (LLY) closed at $795.67 in the latest trading session, marking a -0.08% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 1.1%. Elsewhere ...
Shelby Knowles / Bloomberg via Getty Images Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat moderate-to-severe obstructive ...
Eli Lilly (LLY) stated: “In a win for patients, the judge overseeing Lilly’s International Trade Commission case determined that U.S. Customs and Border Protection should prevent the illicit ...
One night, Stuart was in excruciating pain. The pain killers weren't working. 'Paige, our middle child, stood at the top of our stairs crying saying "I don't want daddy to have cancer".
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback